Study Title
ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Protocol ID
ARST1921
Condition/s
Desmoid Fibromatosis
Recurrent Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
Recurrent Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
Diagnosis Stage
New Diagnosis
Relapse
Relapse
Location
WA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc.
Links
Trial Status
Closed to Recruitment
Sites
Perth Children's Hospital
Christchurch Hospital
Starship Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
12 Months to 18 Years
International registry ID's
NCT04195399
| Study Title | ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors |
|---|---|
| Protocol ID | ARST1921 |
| Disease (Sub Disease) | Desmoid Fibromatosis Recurrent Desmoid Fibromatosis Unresectable Desmoid Fibromatosis |
| Diagnosis Stage | New Diagnosis Relapse |
| Location | WA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI)/ SpringWorks Therapeutics, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT04195399 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 21/09/2020 |
| Sites | Perth Children's Hospital/ Christchurch Hospital / Starship Hospital / |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 12 Months to 18 Years |
| International registry ID's | NCT04195399 |